Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05926583 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Sponsor changed: Janssen Pharmaceutical K.K. to MeiraGTx Ocular UK Ltd
    • Eligibility criteria expanded, about 7 words
    • Publications: details revised at 1 of 1 entry
  2. 4 versions Re-verified since May 7, 2026, no change to tracked fieldsv31-v34
  3. Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised
    v30
  4. 4 versions Re-verified since Dec 12, 2025, no change to tracked fieldsv26-v29
  5. Primary completion date: Sep 16, 2025 to Jun 30, 2027
    • Secondary endpoints: 11 to 3
    v25
Show 23 earlier versionsHide 23 earlier versions
  1. 2 versions Re-verified since Jul 17, 2025, no change to tracked fieldsv23-v24
  2. Study completion date: May 17, 2030 to Nov 12, 2030v22
  3. 5 versions Re-verified since Jan 22, 2025, no change to tracked fieldsv17-v21
  4. Study completion date: Feb 7, 2030 to May 17, 2030v16
  5. 2 versions Re-verified since Sep 10, 2024, no change to tracked fieldsv14-v15
  6. Study completion date: Oct 9, 2029 to Feb 7, 2030v13
  7. 4 versions Re-verified since Apr 23, 2024, no change to tracked fieldsv9-v12
  8. Study completion date: May 10, 2029 to Oct 9, 2029v8
  9. Re-verified, no change to tracked fieldsv7
  10. Primary completion date: Sep 14, 2024 to Sep 16, 2025
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: 7 to 11
    v6
  11. 2 versions Re-verified since Nov 7, 2023, no change to tracked fieldsv4-v5
  12. Start date changed from estimate of Aug 21, 2023 to Sep 12, 2023v3
  13. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jul 24, 2023 to Aug 21, 2023
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the study is to assess the safety and tolerability of bilateral subretinal delivery of adeno-associated virus vector with a serotype 5 capsid human rhodopsin kinase promoter. retinitis pigmentosa guanosine triphosphatase regulator (AAV5-hRKp.RPGR).
Trial Details
NCT Number NCT05926583
Lead Sponsor MeiraGTx Ocular UK Ltd
Conditions
(from sponsor)		 Retinitis Pigmentosa
Related terms Retinitis Pigmentosa
Enrollment 4 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov